Pfizer (PFE) Cash & Current Investments (2009 - 2026)

Pfizer (PFE) has reported Cash & Current Investments for 18 consecutive years, with $13.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments fell 24.5% year-over-year to $13.1 billion; the TTM figure through Mar 2026 stood at $13.1 billion (down 24.5% YoY), while the FY2025 annual figure was $13.6 billion, down 33.6% from the prior year.
• Cash & Current Investments fell to $13.1 billion in Q1 2026 per PFE's latest filing, from $13.6 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $44.8 billion in Q3 2023 and bottomed at $7.1 billion in Q2 2024.
• Historically, Cash & Current Investments has averaged $18.6 billion across 5 years, with a median of $15.0 billion in 2025.
• Annual changes were most pronounced in 2024 — Cash & Current Investments slumped 84.15% — and 2025, when it surged 86.61%.
• Pfizer's Cash & Current Investments stood at $22.7 billion in 2022, then slumped by 44.18% to $12.7 billion in 2023, then soared by 61.36% to $20.5 billion in 2024, then plunged by 33.6% to $13.6 billion in 2025, then decreased by 3.83% to $13.1 billion in 2026.
• Business Quant data shows PFE's Cash & Current Investments at $13.1 billion in Q1 2026, $13.6 billion in Q4 2025, and $15.0 billion in Q3 2025.